Navigation Links
Promising biomarker and candidate tumor suppressor gene identified for colorectal cancer
Date:6/17/2009

Researchers have identified a new candidate tumor suppressor gene in colorectal cancer and examined its use as a potential biomarker in stool samples, according to a new study published online June 17 in the Journal of the National Cancer Institute.

In the study, Manon van Engeland, Ph.D., of the Department of Pathology at Maastricht University Medical Center in the Netherlands, and colleagues examined N-Myc downstream-regulated gene 4 (NDRG4) as a novel tumor suppressor and biomarker.

The researchers analyzed NDRG4 promoter methylation and expression in human colorectal cancer cell lines, noncancerous colon mucosa, and colorectal cancer tissue. Quantitative methylation-specific polymerase chain reaction was used to examine NDRG4 promoter methylation as a biomarker in fecal DNA from 75 colorectal cancer patients and 75 control subjects.

The researchers found that NDRG4 promoter methylation was more prevalent in colorectal cancers than in noncancerous colon mucosa. Its mRNA and protein expression were decreased in colorectal cancer tissue compared with noncancerous colon mucosa. A methylation-specific polymerase chain reaction assay for NDRG4 promoter methylation in stool identified the presence of colorectal cancer in 53% of colorectal cancer cases and correctly categorized a subject as cancer free 100% of the time.

"In conclusion, to our knowledge, this is the first study to describe a tumor suppressor role for NDRG4 in cancer," the authors write. "Our data indicate that NDRG4 promoter methylation is potentially useful as a sensitive and specific noninvasive pre-selection modality for identifying individuals at risk for colorectal cancer for whom colonoscopy is recommended."

In an accompanying editorial, Gad Rennert, M.D., Ph.D., of the Carmel Medical Center and Technion in Haifa, Israel, discusses the concept of molecular testing of stool for early detection of colorectal cancer and where such testing stands today.

"Genetic diagnosis of colorectal cancers and meaningful adenomas has now reached a new phase that, when further fine-tuned, may carry the promise of becoming a suitable and affordable means of prevention and early detection of colorectal cancer in the general population," he writes.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
3. Molecule Promising Against Huntingtons Disease
4. Computerized training of working memory is a promising therapeutic strategy in ADHD
5. Baicalin might be a promising therapeutic tool for severe acute pancreatitis
6. Initial Evaluation of New Nucleus Removal Device Provides Promising Results
7. Promising new TB drug given special status by US and European regulators
8. New Drug Promising Against Tough-to-Treat Kidney Cancer
9. Einstein scientists treat cancer as an infectious disease -- with promising results
10. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... in Central Michigan, has produced another video highlighting one of the many supplemental ... Arts class. Sensei Ed Taylor, a 5 th Degree Black Belt in the ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Program (KOHP), a $500,000 two-year pilot initiative to improve oral health-related awareness, education, ... professional development for health care providers and promote best practices in 10 New ...
(Date:5/25/2016)... MA (PRWEB) , ... May 25, 2016 , ... ... Research Institute (WCRI) compare outcomes of injured workers across 15 states. The ... to work, earnings recovery, access to medical care, and satisfaction with medical care. ...
(Date:5/25/2016)... ... ... Cheryl Bowker of Bowker Insurance Group has been presented with one of the ... ran one of Allstate’s most successful agencies for 48 years, but it was his ... award named for him is not given every year, but only when an agency ...
(Date:5/25/2016)... Puerto Vallarta, Mexico (PRWEB) , ... May 25, 2016 , ... ... menu surrounding the restorative properties of precious stones to complement its new wellness ... spread over two floors and feature a plethora of special services and insuite amenities, ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und ... Überlegenheit in ‚ausgezeichneter plus guter ... Colons    ,      (Logo: ... gab heute neue positive Daten von der MORA-Studie ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... , May 24, 2016 Open ... in Clinical Neurophysiology  Elsevier , a ... and services, today announced the launch of ... access journal that focuses on clinical practice issues in ... reports, clinical series, normal values and didactic reviews. It ...
Breaking Medicine Technology: